Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ripa

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Expert Opinion on Pharmacotherapy|February 5, 2013
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back painKate Miller, Aaron Yarlas, Warren Wen, et al.
Pain Physician|January 11, 2017
Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical StudiesKathleen Campbell, J Walter Kutz, Angela Shoup, et al.
Clinical Therapeutics|November 29, 2007
Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia studyCraig J Landau, William D Carr, Albert J Razzetti, et al.
Clinical Therapeutics|March 1, 1995
The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Nifedipine Study GroupS P Glasser, S R Ripa, K S Allenby, et al.
Pain Practice : the Official Journal of World Institute of Pain|January 21, 2015
Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled TrialsAaron Yarlas, Kate Miller, Warren Wen, et al.
The Clinical Journal of Pain|January 8, 2014
The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and healthKate Miller, Aaron Yarlas, Warren Wen, et al.
Postgraduate Medicine|December 20, 2014
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back painAaron Yarlas, Kate Miller, Warren Wen, et al.
The Journal of Pain|December 4, 2012
A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back painAaron Yarlas, Kate Miller, Warren Wen, et al.
Pain Practice : the Official Journal of World Institute of Pain|April 14, 2015
A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with DepressionAaron Yarlas, Kate Miller, Warren Wen, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Expert Opinion on Pharmacotherapy|February 5, 2013
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back painKate Miller, Aaron Yarlas, Warren Wen, et al.
Pain Physician|January 11, 2017
Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical StudiesKathleen Campbell, J Walter Kutz, Angela Shoup, et al.
Clinical Therapeutics|November 29, 2007
Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia studyCraig J Landau, William D Carr, Albert J Razzetti, et al.
Clinical Therapeutics|March 1, 1995
The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Nifedipine Study GroupS P Glasser, S R Ripa, K S Allenby, et al.
Pain Practice : the Official Journal of World Institute of Pain|January 21, 2015
Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled TrialsAaron Yarlas, Kate Miller, Warren Wen, et al.
The Clinical Journal of Pain|January 8, 2014
The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and healthKate Miller, Aaron Yarlas, Warren Wen, et al.
Postgraduate Medicine|December 20, 2014
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back painAaron Yarlas, Kate Miller, Warren Wen, et al.
The Journal of Pain|December 4, 2012
A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back painAaron Yarlas, Kate Miller, Warren Wen, et al.
Pain Practice : the Official Journal of World Institute of Pain|April 14, 2015
A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with DepressionAaron Yarlas, Kate Miller, Warren Wen, et al.
Pageof 6